solo para uso en investigación
Cat. No.: S2745
| Dianas relacionadas | PI3K Akt mTOR ATM/ATR DNA-PK AMPK PDPK1 PTEN PP2A PDK |
|---|---|
| Otros GSK-3 Inhibidores | CHIR-99021 (Laduviglusib) Laduviglusib (CHIR-99021) Hydrochloride SB216763 TWS119 GSK-3 Inhibitor IX (BIO) LY2090314 Tideglusib SB415286 AR-A014418 1-Azakenpaullone |
| Líneas celulares | Tipo de ensayo | Concentración | Tiempo de incubación | Formulación | Descripción de la actividad | PMID |
|---|---|---|---|---|---|---|
| BGC-823 | Proliferation assay | 50 nM | 48 h | abrogated rLMO3 protein-induced proliferation | 29436606 | |
| HGC-27 | Proliferation assay | 50 nM | 48 h | abrogated rLMO3 protein-induced proliferation | 29436606 | |
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 29435139 | |||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | |||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | |||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | |||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | |||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | |||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 29435139 | |||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | |||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | |||
| Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 29435139 | |||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | |||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | |||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 29435139 | |||
| Haga clic para ver más datos experimentales de líneas celulares | ||||||
| Peso molecular | 486.31 | Fórmula | C20H17Cl2N9O2 |
Almacenamiento (Desde la fecha de recepción) | |
|---|---|---|---|---|---|
| Nº CAS | 252935-94-7 | Descargar SDF | Almacenamiento de soluciones madre |
|
|
| Sinónimos | CT98014 | Smiles | C1=CC(=C(C=C1Cl)Cl)C2=NC(=NC=C2N3C=CN=C3)NCCNC4=NC(=C(C=C4)[N+](=O)[O-])N | ||
|
In vitro |
DMSO
: 10 mg/mL
(20.56 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Paso 1: Introduzca la información a continuación (Recomendado: Un animal adicional para tener en cuenta la pérdida durante el experimento)
Paso 2: Introduzca la formulación in vivo (Esto es solo la calculadora, no la formulación. Por favor, contáctenos primero si no hay una formulación in vivo en la sección de Solubilidad.)
Resultados del cálculo:
Concentración de trabajo: mg/ml;
Método para preparar el líquido maestro de DMSO: mg fármaco predissuelto en μL DMSO ( Concentración del líquido maestro mg/mL, Por favor, contáctenos primero si la concentración excede la solubilidad del DMSO del lote del fármaco. )
Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadirμL PEG300, mezclar y clarificar, luego añadirμL Tween 80, mezclar y clarificar, luego añadir μL ddH2O, mezclar y clarificar.
Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadir μL Aceite de maíz, mezclar y clarificar.
Nota: 1. Por favor, asegúrese de que el líquido esté claro antes de añadir el siguiente disolvente.
2. Asegúrese de añadir el (los) disolvente(s) en orden. Debe asegurarse de que la solución obtenida, en la adición anterior, sea una solución clara antes de proceder a añadir el siguiente disolvente. Se pueden utilizar métodos físicos como el vórtice, el ultrasonido o el baño de agua caliente para ayudar a la disolución.
| Targets/IC50/Ki |
GSK-3β
(Cell-free assay) 0.58 nM
GSK-3α
(Cell-free assay) 0.65 nM
|
|---|---|
| In vitro |
CHIR-98014 inhibits human GSK-3β with Ki of 0.87 nM. This compound is very effective in preventing murine and rat GSK-3. Although it acts as a simple competitive inhibitor of ATP binding, it displays from 500-fold to >1000-fold selectivity for GSK-3 versus 20 other protein kinases including Cdc2, ERK2, Tie-2 and KDR. This inhibitor prevents Cdc2 with IC50 of 3.7 μM. However, it reveals similar potency against the highly homologous ɑ and β isoforms of GSK-3, it is noteworthy that it strongly discriminated between GSK-3 and its closest homologs CDC2 and ERK2. Exposure of insulin receptor-expressing CHO-IR cells or primary rat hepatocytes to increasing concentrations of this chemical results in a two- to three-fold stimulation of the GS activity ratio above basal. The concentrations giving rise to half-maximal GS stimulation (EC50) is 106 nM and 107 nM for CHO-IR and rat hepatocytes, respectively.
|
| Ensayo de quinasa |
Ensayos de quinasas
|
|
Las placas de 96 pocillos de polipropileno se llenan con 300 μL/pocillo de tampón (50 mM Tris HCl, 10 mM MgCl2, 1 mM EGTA, 1 mM ditiotreitol, 25 mM β-glicerofosfato, 1 mM NaF, 0,01% BSA, pH 7,5) que contiene la quinasa, el sustrato peptídico y cualquier activador. CHIR-98014 o los controles se añaden en 3,5 μL de DMSO, seguido de 50 μL de stock de ATP para obtener una concentración final de 1 μM de ATP en todos los ensayos libres de células. Después de la incubación, se transfieren alícuotas de 100 μL por triplicado a placas Combiplate ocho que contienen 100 μL/pocillo de 50 μM de ATP y 20 mM de EDTA. Después de 1 hora, los pocillos se enjuagan cinco veces con PBS, se llenan con 200 μL de líquido de centelleo, se sellan, se dejan 30 minutos y se cuentan en un contador de centelleo. Todos los pasos se realizan a temperatura ambiente.
|
|
| In vivo |
GSK-3 inhibitor CHIR-98014 activates the GS activity ratio in isolated type I skeletal muscle from insulin-sensitive lean Zucker and from insulin-ressitant ZDF rats. Soleus muscle isolated from ZDF rats shows significant resistance to insulin for activation of GS but responded to 500 nM of this compound to the same extent (40% increase) as muscle from lean Zucker rats. Notably, GS activation by insulin plus this chemical is additive in muscle from lean Zucker rats and greater than additive in muscle from the ZDF rats. Total GS activity is not altered by either this inhibitor or insulin in these cells and muscles. Meanwhile, this compound does not influence the insulin dose-response in muscle from lean animals. The reduction in hyperglycemia and improved glucose disposal are not limited to db/db mice and ZDF rats, as similar results are observed with ob/ob mice, diet-induced diabetic C57BL/6 mice, and glucose-intolerant SHHF rats treated with this chemical. Additionally, this compound decreases the phosphorylation (Ser396) of tau protein in the cortex and hippocampus of postnatal rats.
|
Referencias |
|
| Métodos | Biomarcadores | Imágenes | PMID |
|---|---|---|---|
| Western blot | p-AKT / AKT / p-GSK3β / GSK3β / β-catenin |
|
28415692 |
| Growth inhibition assay | Cell viability |
|
24779365 |